Scarica l'app Stockscreener
19.65
2.25%
-0.3946
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DYN Giù?
Forum
Previsione
Dyne Therapeutics Inc Borsa (DYN) Ultime notizie
First Week of February 2026 Options Trading For Dyne Therapeutics (DYN) - Nasdaq
Dyne Therapeutics appoints Vikram Karnani to board of directors By Investing.com - Investing.com Nigeria
Dyne Therapeutics Bets Big On Breakthrough Muscle Disease Treatments - Finimize
Dyne Therapeutics (DYN): Reaffirmed Buy Ratings Prompt Fresh Look at Valuation After Neuromuscular Data Update - Yahoo Finance
Dyne Therapeutics appoints Vikram Karnani to board of directors - Investing.com
Dyne Therapeutics Appoints Vikram Karnani to Board - TipRanks
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors - The Manila Times
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors to Support Commercialization Efforts - Quiver Quantitative
Dyne Therapeutics Appoints Vikram Karnani To Board Of Directors - TradingView — Track All Markets
Why Analysts See a Huge Upside for Dyne Therapeutics (DYN) - Finviz
Dyne Therapeutics (DYN) Price Target Increased by 12.57% to 39.97 - Nasdaq
Dyne Therapeutics, Inc. $DYN Shares Purchased by Squarepoint Ops LLC - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Understanding the Setup: (DYN) and Scalable Risk - news.stocktradersdaily.com
Will Dyne Therapeutics Inc. stock gain from government policiesTrade Analysis Report & Daily Oversold Stock Bounce Ideas - ulpravda.ru
How risky is Dyne Therapeutics Inc. stock nowJuly 2025 Levels & Precise Swing Trade Alerts - DonanımHaber
Will Dyne Therapeutics Inc. stock reach all time highs in 2025Quarterly Trade Summary & Low Risk Profit Maximizing Plans - DonanımHaber
DYN (Dyne Therapeutics) EV-to-OCF : -6.50 (As of Dec. 19, 2025) - GuruFocus
Can Dyne Therapeutics Inc. stock deliver consistent earnings growth2025 Volatility Report & Safe Swing Trade Setup Alerts - DonanımHaber
Dyne Therapeutics (DYN) climbs 9.5% on stellar results for DMD therapy candidate - MSN
Dyne to seek accelerated approval of DMD drug on Phase I/II data - MSN
Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity - MSN
Dyne Therapeutics (DYN) Gets a Buy from Stifel Nicolaus - The Globe and Mail
Oppenheimer upgrades Dyne Therapeutics to outperform, raises target to $40 - MSN
Sarepta rises as HHS adds Duchenne muscular dystrophy to newborn screenings - Seeking Alpha
Evercore ISI Maintains and Lowers Price Target for Dyne Therapeu - GuruFocus
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Frazier Life Sciences Management L.P. Has $14.34 Million Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
TFG Asset Management GP Ltd Acquires New Stake in Dyne Therapeutics, Inc. $DYN - MarketBeat
Braidwell LP Has $31.16 Million Stock Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics offers to sell $300M in common stock - MSN
WilmerHale Advises Dyne Therapeutics on its $402.5 Million Public Offering of Common Stock - WilmerHale
Why Dyne Therapeutics stock was a big winner on Wednesday - MSN
Stifel Nicolaus Reaffirms Their Buy Rating on Dyne Therapeutics (DYN) - The Globe and Mail
HighVista Strategies LLC Sells 52,096 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne’s Zeleciment Basivarsen Shows Sustained Gains in DM1 Trial at One Year - MSN
Armistice Capital LLC Has $24.37 Million Stock Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
Stifel Maintains Dyne Therapeutics (DYN) Buy Recommendation - Nasdaq
Dyne Therapeutics raises $402.5 million in upsized public offering By Investing.com - Investing.com Nigeria
Dyne Therapeutics raises $402.5 million in upsized public offering - Investing.com
Dyne Therapeutics prices $350 stock offering - MSN
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares - The Manila Times
Dyne Therapeutics Closes $402.5 Million Upsized Public Offering of Common Stock - Quiver Quantitative
Dyne Therapeutics (Nasdaq: DYN) closes upsized offering of 21,827,549 shares at $18.44 - Stock Titan
Dyne Therapeutics (NASDAQ:DYN) Price Target Raised to $39.00 at Stifel Nicolaus - MarketBeat
Dyne, citing positive trial data, to ask FDA to approve DMD therapy - Muscular Dystrophy News
Why Dyne Therapeutics stock tanked on Tuesday - MSN
Dyne Therapeutics 18.98M-share secondary priced at $18.44 - MSN
Stifel Raises Price Target for Dyne Therapeutics (DYN) to $39.00 - GuruFocus
Dyne Therapeutics Shares Rise After Announcing Positive Topline Results for z-rostudirsen in Phase 1/2 DMD Trial - Insider Monkey
Dyne Therapeutics price target raised to $23 from $21 at Bernstein - MSN
Dyne Therapeutics (DYN) Upgraded by Oppenheimer, Potential 50% U - GuruFocus
0.20%
0.75%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):